United States· US:66658-231_48e6af70-cd93-3f1d-e063-6394a90a8104

Synagis

A palivizumab product containing palivizumab, registered in United States by Swedish Orphan Biovitrum AB (publ). The same ATC class is registered in 13 of our 19 countries.

ATC J06BD01US label

Checked against FDA National Drug Code directory (United States) on

Informational only — not a medical device.

SOURCE REGISTER · USFDA National Drug Code directory (Unite…normalisedSynagisATCJ06BD01REGISTER NO.US:66658-231_48e6af70…PACKS LISTED2CHECKEDJuly 26, 2026

Where it is registered

Palivizumab is registered in 13 of 19 countries.

Countries holding a registration under ATC J06BD01 (palivizumab), each read from that country’s own register.

  • This record: United States, from FDA National Drug Code directory (United States)
  • 9 of them publish a price we can compare per daily dose

Palivizumab · ATC J06BD01

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of palivizumab costs, country by country.

Normalised to the WHO defined daily dose (3.75 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Palivizumab · price per daily dose (3.75 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$51.40
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

FDA National Drug Code directory (United States)
Active substance
PALIVIZUMAB
Manufacturer
Swedish Orphan Biovitrum AB (publ)
Country
United States (US)
ATC code
J06BD01
ATC class
Palivizumab
Defined daily dose
3.75 mg, P
Reimbursed
Not published by this register
Source register
FDA National Drug Code directory (United States)
Last checked
July 26, 2026

Packs & prices · 2

  • ndc11
    66658-231-01
  • ndc11
    6665823101
    1 mL in 1 VIAL, SINGLE-DOSE (66658-231-01)

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Palivizumab in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All palivizumab products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Synagis
  • Liechtenstein · Synagis
  • Norway · Synagis

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/37529555-5549-486d-88e6-a4e0765ef7b0
GET /v1/drugs/37529555-5549-486d-88e6-a4e0765ef7b0?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "route": "INTRAMUSCULAR",
  "source": "ndc",
  "strength": "100",
  "substance": "PALIVIZUMAB",
  "productndc": "66658-231",
  "dosage_form": "INJECTION, SOLUTION",
  "dea_schedule": null,
  "strength_unit": "mg/mL",
  "application_number": "BLA103770",
  "marketing_category": "BLA"
}

See everything about palivizumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.